Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: VRX
  • CUSIP:
Key Metrics:
  • Previous Close: $26.42
  • 50 Day Moving Average: $28.16
  • 200 Day Moving Average: $27.99
  • 52-Week Range: $18.55 - $182.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.43
  • P/E Growth: 0.62
  • Market Cap: $9.18B
  • Outstanding Shares: 347,535,000
  • Beta: 0.07
Profitability:
  • Net Margins: -9.29%
  • Return on Equity: 46.59%
  • Return on Assets: 5.68%
Debt:
  • Debt-to-Equity Ratio: 5.70%
  • Current Ratio: 1.38%
  • Quick Ratio: 1.06%
Additional Links:
Companies Related to Valeant Pharmaceuticals International:

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (?)
Ratings Breakdown: 4 Sell Ratings, 14 Hold Ratings, 10 Buy Ratings
Consensus Rating:Hold (Score: 2.21)
Consensus Price Target: $52.10 (97.21% upside)

Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/26/2016RBC Capital MarketsReiterated RatingSector Perform$46.00View Rating Details
9/20/2016Deutsche Bank AGInitiated CoverageHold$30.00View Rating Details
9/18/2016Wells Fargo & Co.Reiterated RatingSell$19.50View Rating Details
9/7/2016Morgan StanleyReiterated RatingOverweight$42.00View Rating Details
8/19/2016Piper Jaffray Cos.Set Price TargetSell$22.00View Rating Details
8/19/2016Canaccord GenuityReiterated RatingHold$31.00 -> $33.00View Rating Details
8/18/2016MizuhoReiterated RatingUnderperform$11.00View Rating Details
8/13/2016TD SecuritiesReiterated RatingBuy$38.00View Rating Details
8/11/2016GuggenheimReiterated RatingBuy$55.00View Rating Details
8/10/2016BTIG ResearchReiterated RatingNeutralView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuy$40.00View Rating Details
8/10/2016Royal Bank Of CanadaBoost Price TargetSector Perform$31.00 -> $36.00View Rating Details
8/9/2016Rodman & RenshawLower Price TargetBuy$90.00 -> $81.00View Rating Details
7/26/2016ScotiabankReiterated RatingSector Perform$35.00 -> $32.00View Rating Details
7/25/2016JPMorgan Chase & Co.Set Price TargetHold$35.00View Rating Details
7/20/2016BMO Capital MarketsReiterated RatingMarket Perform$26.00View Rating Details
7/6/2016Stifel NicolausReiterated RatingBuy$55.00View Rating Details
6/7/2016Barclays PLCReiterated RatingHold$34.00View Rating Details
5/29/2016SusquehannaReiterated RatingHold$105.00View Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00View Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00View Rating Details
12/21/2015Bank of America Corp.Reiterated RatingBuyView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldView Rating Details
11/2/2015Goldman Sachs Group Inc.DowngradeBuy -> Neutral$180.00 -> $122.00View Rating Details
10/23/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyView Rating Details
7/20/2015JMP SecuritiesBoost Price TargetMarket Outperform$48.00 -> $50.00View Rating Details
7/10/2015Howard WeilInitiated CoverageOutperform$290.00View Rating Details
4/30/2015Cantor FitzgeraldBoost Price TargetBuy$222.00 -> $271.00View Rating Details
2/25/2015CRT CapitalBoost Price TargetBuy$180.00 -> $220.00View Rating Details
10/20/2014AegisReiterated RatingBuyView Rating Details
10/8/2014ING GroupUpgradeBuyView Rating Details
(Data available from 9/29/2014 forward)

Earnings

Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
Current Year EPS Consensus Estimate: $6.53 EPS
Next Year EPS Consensus Estimate: $7.70 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161$1.60$1.60$1.60
Q3 20161$1.83$1.83$1.83
Q4 20161$2.10$2.10$2.10
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Ownership Percentage: 16.37%
Institutional Ownership Percentage: 63.59%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
DateHeadline
capitalcube.com logoValeant Pharmaceuticals International, Inc. – Value Analysis (NYSE:VRX) : September 28, 2016 (NYSE:VRX)
www.capitalcube.com - September 28 at 7:47 PM
investornewswire.com logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) : Quarterly EPS At $2.01 - Investor Newswire (NYSE:VRX)
www.investornewswire.com - September 27 at 9:44 AM
capitalcube.com logoValeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bearish Manner : VRX-US : September 27, 2016 (NYSE:VRX)
www.capitalcube.com - September 27 at 9:44 AM
realistinvestor.com logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) Accounts Payable At $425.9 - RealistInvestor.com (NYSE:VRX)
www.realistinvestor.com - September 26 at 8:00 PM
News IconFinancial Watchlist of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Newburgh Press (NYSE:VRX)
newburghpress.com - September 26 at 8:00 PM
News IconStock under Consideration- Valeant Pharmaceuticals International, Inc.'s (VRX) - Hot Stocks Point (NYSE:VRX)
www.hotstockspoint.com - September 25 at 6:49 AM
seekingalpha.com logoValeant Pharmaceuticals: How Much Downside? - Seeking Alpha (NYSE:VRX)
seekingalpha.com - September 25 at 6:49 AM
thecountrycaller.com logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) to Write Down 90% or More of Sprout: Analyst - TCC (NYSE:VRX)
www.thecountrycaller.com - September 24 at 6:56 AM
blogs.barrons.com logoInvesting for the Next 100 Years (NYSE:VRX)
blogs.barrons.com - September 23 at 7:22 PM
News IconTrader's Buzzer – Valeant Pharmaceuticals International, Inc.'s (VRX) - Hot Stocks Point (NYSE:VRX)
www.hotstockspoint.com - September 23 at 6:49 AM
seekingalpha.com logoValeant Coming Apart - Seeking Alpha (NYSE:VRX)
seekingalpha.com - September 23 at 6:49 AM
thecountrycaller.com logoDeutsche Bank AG (DB) Covers Valeant Pharmaceuticals International, Inc. (VRX) Amid Rising Dermatology Expectations (NYSE:VRX)
www.thecountrycaller.com - September 21 at 11:53 AM
News IconInvestor's Alert - Valeant Pharmaceuticals International, Inc.'s (VRX ... - Hot Stocks Point (NYSE:VRX)
www.hotstockspoint.com - September 17 at 7:23 PM
streetinsider.com logoValeant Pharma (VRX) Clarifies Discount And Rebate Program For Nitropress And Isuprel - StreetInsider.com (NYSE:VRX)
www.streetinsider.com - September 16 at 7:43 PM
News IconShares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) & Host Hotels and Resorts Inc (NYSE:HST) Stocks News Update: Thursday (NYSE:VRX)
www.newsismoney.com - September 16 at 11:40 AM
marketrealist.com logoWhy Does Bill Miller Like Valeant Pharmaceuticals? (NYSE:VRX)
marketrealist.com - September 16 at 11:40 AM
News IconStock Perspective: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Earnings in View - Frisco Fastball (NYSE:VRX)
friscofastball.com - September 15 at 8:08 PM
fool.com logoThe Single Most Important Metric to Determine if Valeant Pharmaceuticals Is a Buy (NYSE:VRX)
www.fool.com - September 15 at 8:08 PM
thestreet.com logoGuggenheim Analyst Chen Takes Bullish Outlook On Valeant's (VRX) Growth Potential (NYSE:VRX)
www.thestreet.com - September 14 at 8:14 PM
investing.com logoBill Miller: Valeant shares could post 25-30 percent returns over five years (NYSE:VRX)
www.investing.com - September 14 at 12:23 PM
News IconValeant Pharmaceuticals International, Inc. (NYSE:VRX) Shares Handed One Year Price Objective - Frisco Fastball (NYSE:VRX)
friscofastball.com - September 12 at 7:31 PM
streetinsider.com logoEyegate Pharma (EYEG) Announces Receipt of Additional ... - StreetInsider.com (NYSE:VRX)
www.streetinsider.com - September 12 at 7:31 PM
News IconValeant Pharmaceuticals International, Incorporated (NYSE:VRX) Upcoming Earnings: What matter for investors? - The Voice Registrar (NYSE:VRX)
voiceregistrar.com - September 12 at 7:31 PM
News IconUpdate on Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for the day (NYSE:VRX)
twincountynews.com - September 11 at 6:55 AM
thecountrycaller.com logoValeant Pharmaceuticals International, Inc. (NYSE:VRX) Continues ... - TCC (NYSE:VRX)
www.thecountrycaller.com - September 10 at 7:19 AM
News IconThe Sell-side Consensus is in on Valeant Pharmaceuticals International, Inc. (NYSE:VRX); Earnings & Target Updates - National Daily Press (NYSE:VRX)
www.nationaldailypress.com - September 9 at 7:36 PM
marketrealist.com logoBill Ackman's Stances on Valeant Pharmaceuticals and Herbalife - Market Realist (NYSE:VRX)
marketrealist.com - September 9 at 7:36 PM
thestreet.com logoTeva Discusses EpiPen Comps as Host of Generics Unveiled (NYSE:VRX)
www.thestreet.com - September 9 at 7:36 PM
investopedia.com logoAckman's Pershing Square Bets on Chipotle (CMG, VRX) - Investopedia (NYSE:VRX)
www.investopedia.com - September 8 at 11:55 AM
seekingalpha.com logoValeant CEO comments on asset sales - Seeking Alpha (NYSE:VRX)
seekingalpha.com - September 8 at 11:55 AM
finance.yahoo.com logoThe EpiPen isn't the only drug that's more than doubled in price (NYSE:VRX)
finance.yahoo.com - September 8 at 11:55 AM
investopedia.com logoAckman's Pershing Square Bets on Chipotle (CMG, VRX) (NYSE:VRX)
www.investopedia.com - September 7 at 11:54 AM
streetinsider.com logoValeant Pharma (VRX), Progenics (PGNX) Announce Commercial Launch of RELISTOR as OIC Treatment - StreetInsider.com (NYSE:VRX)
www.streetinsider.com - September 6 at 8:06 PM
News IconValeant Pharmaceuticals International, Inc.'s (VRX) - Cosumnes Connection (subscription) (NYSE:VRX)
www.crcconnection.com - September 3 at 6:59 PM
News IconValeant Pharmaceuticals Intl Inc (NYSE:VRX): Price Reaction History (NYSE:VRX)
magseriesusa.net - September 2 at 7:50 PM
News IconMajor Stock of Recent Trade: Valeant Pharmaceuticals International, Inc.'s (VRX) - Cosumnes Connection (subscription) (NYSE:VRX)
www.crcconnection.com - September 1 at 11:21 AM
thecountrycaller.com logoValeant Pharmaceuticals International, Inc.'s (VRX) Agreement with Orexigen Therapeutics Cheers Investors - TCC (NYSE:VRX)
www.thecountrycaller.com - September 1 at 11:21 AM
investopedia.com logoBill Ackman's Cry: "Worst Period Of Performance" (HLN, VRX) (NYSE:VRX)
www.investopedia.com - September 1 at 11:21 AM
finance.yahoo.com logoChou RRSP Fund Buys Valeant (NYSE:VRX)
finance.yahoo.com - September 1 at 11:21 AM
finance.yahoo.com logoElizabeth Warren just demanded Mylan come clean about one of the biggest secrets in pharma (NYSE:VRX)
finance.yahoo.com - September 1 at 11:21 AM
fool.com logoIf I Were a Valeant Pharmaceuticals Shareholder, This Would Infuriate Me (NYSE:VRX)
www.fool.com - September 1 at 11:21 AM
thecountrycaller.com logoValeant Pharmaceuticals International, Inc. (VRX) Sued In New York Over Philidor Ties - TCC (NYSE:VRX)
www.thecountrycaller.com - August 30 at 7:53 PM
News IconWhich way Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earnings may go - The Voice Registrar (NYSE:VRX)
voiceregistrar.com - August 30 at 7:53 PM
finance.yahoo.com logo5:01 pm Valeant Pharma announces that Chairman and CEO Joseph C. Papa will participate in two healthcare conferences in September (NYSE:VRX)
finance.yahoo.com - August 30 at 7:53 PM
benzinga.com logoOrexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada - Benzinga (NYSE:VRX)
www.benzinga.com - August 30 at 11:29 AM
News IconToday's Top Gainers in the Market Valeant Pharmaceuticals International, Inc. (NYSE:VRX) from Healthcare - The Daily Leicester (NYSE:VRX)
thedailyleicester.com - August 29 at 7:16 AM
finance.yahoo.com logoTime to Shift Your Focus (NYSE:VRX)
finance.yahoo.com - August 28 at 7:09 AM
thecountrycaller.com logoValeant Pharmaceuticals International, Inc. (VRX) Shares Are Rising Following Management Meeting: Here's Why - TCC (NYSE:VRX)
www.thecountrycaller.com - August 27 at 7:13 AM
News IconTop Gainers of the Day: Valeant Pharmaceuticals International, Inc. (NYSE:VRX) from Drug Delivery (NYSE:VRX)
twincountynews.com - August 26 at 7:45 PM
thecountrycaller.com logoValeant Pharmaceuticals International, Inc. (VRX) Shares Are Rising Following Management Meeting: Here's Why (NYSE:VRX)
www.thecountrycaller.com - August 26 at 11:01 AM

Social

Valeant Pharmaceuticals International (NYSE:VRX) Chart for Thursday, September, 29, 2016


Last Updated on 9/29/2016 by MarketBeat.com Staff